AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 8998919
Drug: 23-valent vaccine
RxNorm normalized name: Pneumococcal 23-valent vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 23-valent vaccine of capsular polysaccharides (Pneumovax 23)
Trial: 1768820
Drug: Propofol (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (1.5 mg/kg)
Trial: 26576424
Drug: Propofol (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (1.5 mg/kg) + Remifentanil (0.05 μg/kg)
Trial: 23995984
Drug: Liberal RBC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liberal RBC transfusion strategy (Hb 10.8 g/dl)
Trial: 11875365
Drug: Tolbutamide (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolbutamide (500 mg)
Trial: 6794584
Drug: Lysine acetyl
RxNorm normalized name: Lysine acetylcysteinate
DrugBank: Nacystelyn (DB17839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lysine acetyl salicylate (LAS) 1.8 g
Trial: 17397061
Drug: Sham treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham treatment (initial 10-week sham treatment)
Trial: 19160722
Drug: Metoprolol 100
RxNorm normalized name: metoprolol 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol 100 mg o.d.
Trial: 12830340
Drug: Amlodipine 5
RxNorm normalized name: amlodipine 5 MG
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amlodipine 5 mg o.d.
Trial: 8387912
Drug: Isabgol husk
RxNorm normalized name: Psyllium Husk
DrugBank: Plantago seed (DB11097)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isabgol husk (25 g) added to low-fibre diet
Trial: 3111669
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg sodium fluoride (NaF) + 1 g calcium
Trial: 3111669
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg sodium fluoride (NaF) + calcium
Trial: 19788472
Drug: Zolmitriptan 5
RxNorm normalized name: zolmitriptan 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zolmitriptan 5 mg
Trial: 10326217
Drug: Weekly L-asparaginase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly L-asparaginase (l-Asp) during maintenance therapy as a late intensification
Trial: 10326217
Drug: Standard maintenance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard maintenance therapy without additional L-asparaginase (l-Asp)
Trial: 10326217
Drug: Full dose
RxNorm normalized name: BayRHo-D Full Dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full dose of daunorubicin (DNR, 450 mg/m2 in total)
Trial: 10326217
Drug: Overall treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall treatment protocol AL841
Trial: 10326217
Drug: Complete remission
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complete remission (CR) achieved with three-drug induction
Trial: 1937073
Drug: Control (fellow
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (fellow eye, no treatment)
Trial: 31124409
Drug: Drug treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug treatment involving COMT modulation
Trial: 31210343
Drug: Institute of
RxNorm normalized name: COVID-19 VVnr Non-US Vaccine (CanSino Biological Inc./Beijing Institute of Biotechnology
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Institute of Medicine (IOM) standards compliance
Trial: 31832225
Drug: Delayed-release dimethyl
RxNorm normalized name: dimethyl fumarate Delayed Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed-release dimethyl fumarate (DMF)
Trial: 23972415
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (treatment-as-usual)
Trial: 15347035
Drug: Nimodipine (90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nimodipine (90 mg/day during 10 days)
Trial: 18559696
Drug: Captopril (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (25 mg)
Trial: 31900080
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D (50,000 IU fortnightly) + Calcium (500 mg daily)
Trial: 27225739
Drug: 8 mg
RxNorm normalized name: alloin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg lornoxicam (Group L)
Trial: 27225739
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg paracetamol (Group P)
Trial: 24458173
Drug: Placebo (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (100 mL water)
Trial: 23782587
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg vildagliptin twice daily co-administered with 0.2 mg voglibose three times daily
Trial: 16767422
Drug: Tryptophan (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tryptophan (1 g 3x a day)
Trial: 15333400
Drug: Bupivacaine 10
RxNorm normalized name: BUPivacaine 100 mg parenteral implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 10 mg
Trial: 14531252
Drug: Bupivacaine 12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 12.5 mg
Trial: 9570604
Drug: Bupivacaine 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 15 mg
Trial: 14531252
Drug: Tetracaine 10
RxNorm normalized name: tetracaine 10 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetracaine 10 mg
Trial: 17276952
Drug: Alendronate 10
RxNorm normalized name: ALENDRONATE 10MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alendronate 10 mg daily
Trial: 453496
Drug: Etomidate (intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etomidate (intravenous injection)
Trial: 22153012
Drug: Xingnaojing (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xingnaojing (20 ml/d i.v. drip) + L-carnitine (2 g/d i.v. drip)
Trial: 22153012
Drug: Xingnaojing (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xingnaojing (20 ml/d i.v. drip)
Trial: 19826292
Drug: Sublingual ergogenic
RxNorm normalized name: ROGENIC TABS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual ergogenic spray containing vitamins, minerals, amino acids, and a coenzyme
Trial: 19766760
Drug: Pomegranate juice
RxNorm normalized name: pomegranate juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pomegranate juice (240 ml/day)
Trial: 2236581
Drug: Nimodipine 90
RxNorm normalized name: Nimodipine
DrugBank: Nimodipine (DB00393)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nimodipine 90 mg administered orally in divided doses for 12 weeks
Trial: 29484638
Drug: GDC-0853 (≤600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GDC-0853 (≤600 mg, single ascending dose; ≤250 mg twice daily; ≤500 mg once daily for 14 days)
Trial: 29484638
Drug: GDC-0853 (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GDC-0853 (100 mg, once daily)
Trial: 28827417
Drug: 1,200 mg
RxNorm normalized name: lecithin 1,200 mg ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,200 mg rifampin
Trial: 28827417
Drug: rifampin (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rifampin (600 mg, 900 mg, 1,200 mg)
Trial: 20298323
Drug: ICS (fluticasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICS (fluticasone propionate) + LABA (salmeterol) (500 mcg/50 mcg bd)
Trial: 20298323
Drug: ICS alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICS alone (500 mcg bd)
Trial: 16176606
Drug: Soya foods
RxNorm normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soya foods (two daily servings including tofu, soya milk, soya nuts, and soya protein powder; equivalent to 50 mg isoflavones and 5-22 g soya protein per serving)
Trial: 12548322
Drug: Outpatient induction
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Outpatient induction with intravaginal controlled-release prostaglandin-E2 (CR-PGE2)
Trial: 7697674
Drug: Diltiazem (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem (0.25 mg/kg)
Trial: 17967668
Drug: Esmolol (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esmolol (0.5 mg/kg)
Trial: 1846331
Drug: 0.25 mg
RxNorm normalized name: biotin 0.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 mg intravenous timolol
Trial: 1846331
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg quinidine pretreatment
Trial: 24797376
Drug: Iron sucrose
RxNorm normalized name: Iron Sucrose
DrugBank: Iron sucrose (DB09146)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron sucrose 100 mg IV thrice weekly for up to 2 weeks
Trial: 22278344
Drug: All treatment
RxNorm normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All treatment groups (84 mg, 126 mg, and placebo)
Trial: 15172090
Drug: Tibolone (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tibolone (2.5 mg per day)
Trial: 3577356
Drug: Trivalent split
RxNorm normalized name: INFLUENZA VIRUS,TRIVALENT SPLIT VACCINE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trivalent split vaccine (15 micrograms haemagglutinin of A-H3N2, A-H1N1, and B strains)
Trial: 3577356
Drug: Booster injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Booster injection of the same vaccine dosage four weeks after the first immunization
Trial: 30712326
Drug: Good psychiatric
RxNorm normalized name: miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Good psychiatric management treatment with the addition of the Motive‐Oriented Therapeutic Relationship
Trial: 30712326
Drug: Good psychiatric
RxNorm normalized name: miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Good psychiatric management treatment
Trial: 30541217
Drug: Berberine (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Berberine (0.4 g, 3 times a day)
Trial: 30541217
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (only hypoglycemic agents)
Trial: 24742381
Drug: mHealth cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mHealth cognitive stimulation therapy (therapist-assisted) for 4 weeks, 2-3 days/week
Trial: 24742381
Drug: Control (treatment-as-usual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (treatment-as-usual with no neuropsychological intervention)
Trial: 10815576
Drug: Oral health
RxNorm normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral health promotion programme
Trial: 7557599
Drug: Radical surgery
RxNorm normalized name: Campsis radicans flower extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radical surgery without preoperative adjuvant chemotherapy (Control)
Trial: 2148321
Drug: Topical administration
RxNorm normalized name: Octocaine 5 % Ointment for Oral and Topical Administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical administration of glucosyltransferase (GTF) combined with aluminum phosphate (AP) daily for 5 days.
Trial: 7387491
Drug: Bromocriptine mesylate
RxNorm normalized name: Bromocriptine Mesylate
DrugBank: Bromocriptine (DB01200)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bromocriptine mesylate (2.5 to 20.0 mg daily)
Trial: 31609716
Drug: Trunk‐based vibrotactile
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trunk‐based vibrotactile sensory augmentation (SA) during balance exercises
Trial: 26893187
Drug: Dutasteride 0.5
RxNorm normalized name: dutasteride 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dutasteride 0.5 mg p.o. once daily for 52 weeks
Trial: 22033341
Drug: Buccal envelope
RxNorm normalized name: Zaire ebolavirus envelope glycoprotein Injection [Ervebo]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buccal envelope flap
Trial: 16042664
Drug: Sotalol +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sotalol + Telithromycin (800 mg)
Trial: 9863281
Drug: Low-dose etretinate
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose etretinate combined with eicosapentaenoic acid
Trial: 9863281
Drug: Low-dose etretinate
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose etretinate alone
Trial: 8548058
Drug: Human galanin
RxNorm normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Human galanin (hGAL) infusion (80 pmol.kg‐1.min‐1) for 60 minutes
Trial: 1978443
Drug: High-dose intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose intravenous immunoglobulins (0.4 g/kg body weight IVIG every other week for 26 weeks)
Trial: 103182
Drug: 2% aqueous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% aqueous solution of sodium cromoglycate
Trial: 30683457
Drug: Low-dose colchicine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose colchicine (0.5 mg/day)
Trial: 20839670
Drug: Transepithelial treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transepithelial treatment (group 1)
Trial: 20839670
Drug: Subepithelial treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subepithelial treatment (group 2)
Trial: 10445773
Drug: Ropivacaine 1%
RxNorm normalized name: ROPivacaine 1% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 1% with 2% lidocaine and hyaluronidase 15 IU x mL(‐1)
Trial: 10445773
Drug: Bupivacaine 0.75%
RxNorm normalized name: BUPivacaine 0.75% injectable kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 0.75% with 2% lidocaine and hyaluronidase 15 IU x mL(‐1)
Trial: 14657866
Drug: Maternal serum
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maternal serum estradiol levels (mean 7.87 nmol/L in asthmatic children)
Trial: 14657866
Drug: Maternal serum
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maternal serum free estradiol levels (mean 149.5 pmol/L in asthmatic children)
Trial: 8210915
Drug: Intra-arterial infusion
RxNorm normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intra-arterial infusion of Adriamycin followed by LAK cells
Trial: 3535544
Drug: Gradual tapering
RxNorm normalized name: mitapivat
DrugBank: Mitapivat (DB16236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gradual tapering of alprazolam
Trial: 27628038
Drug: Placebo granules,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo granules, twice daily for 6 months
Trial: 22909147
Drug: OLM/AML (dual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OLM/AML (dual therapy)
Trial: 28701487
Drug: Medication alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication alone
Trial: 19943833
Drug: Open treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open treatment with antidepressant medication
Trial: 19043609
Drug: Inhalation of
RxNorm normalized name: Ocean brand of sodium chloride Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation of fucose/galactose solution for 21 days
Trial: 14616169
Drug: Oral Group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Group (intravenous omeprazole plus placebo followed by 7 days of oral omeprazole, clarithromycin and amoxicillin b.d.)
Trial: 6189328
Drug: 0.2 mg/1
RxNorm normalized name: Dihydrotachysterol 0.2 MG/1 ML Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg/1 trioxsalen bath PUVA therapy
Trial: 6189328
Drug: equipotent methoxsalen
RxNorm normalized name: Methoxsalen
DrugBank: Methoxsalen (DB00553)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: equipotent methoxsalen bath PUVA therapy
Trial: 2864945
Drug: Pancuronium bromide
RxNorm normalized name: Pancuronium Bromide
DrugBank: Pancuronium (DB01337)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pancuronium bromide administered during vecuronium-induced partial neuromuscular blockade
Trial: 30659073
Drug: Visit-to-visit variability
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Visit-to-visit variability (VVV) of fasting blood glucose (FBG) defined as the SD of FBG measurements (≥26.4 mg/dL)
Trial: 23138807
Drug: Trial administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trial administration
Trial: 16467656
Drug: Valsartan (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan (160 mg)
Trial: 3519416
Drug: Furosemide (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Furosemide (40 mg)
Trial: 7514046
Drug: Placebo and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo and G-CSF
Trial: 25812826
Drug: Prolonged Exposure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged Exposure Therapy for Adolescents (PE-A)
Trial: 10976551
Drug: Quinidine sulfate
RxNorm normalized name: Quinidine Sulfate
DrugBank: Quinidine (DB00908)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Quinidine sulfate (200 mg single oral dose)
Trial: 3543073
Drug: Lactate 12%
RxNorm normalized name: AMMONIUM LACTATE 12% CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactate 12% lotion applied twice daily for 4 weeks
Trial: 22445938
Drug: Preparation with
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preparation with polyethylene glycol on the morning of the colonoscopy (study group)
Trial: 22445938
Drug: Preparation with
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preparation with polyethylene glycol on the previous afternoon (control group)
Trial: 12033657
Drug: Drug Abuse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug Abuse and Resistance Education (DARE-A)
Trial: 10715368
Drug: Ethinyl estradiol
RxNorm normalized name: Ethinyl Estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ethinyl estradiol in triphasic combination with norgestimate
Trial: 2026464
Drug: Level I
RxNorm normalized name: BENZOYL PEROXIDE 25 mg in 1 mL TOPICAL GEL [DermaClear Purity Cleanser Level I]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Level I T, 150-300 mg (n = 24)
Trial: 30612986
Drug: Tapinarof 1%
RxNorm normalized name: TAPINAROF 1% CREAM,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tapinarof 1% twice daily
Trial: 1631487
Drug: Chlorhexidine/fluoride gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorhexidine/fluoride gel
Trial: 6091840
Drug: Intravenous bicarbonate
RxNorm normalized name: Potassium Bicarbonate
DrugBank: Potassium bicarbonate (DB11098)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous bicarbonate (150 mmol)
Trial: 28456864
Drug: Engerix B®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Engerix B® (40 μg, 4 doses at 0, 1, 2, and 6 months)
Trial: 3142949
Drug: Peripheral parenteral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peripheral parenteral nutrition (PPN)
Trial: 24152421
Drug: Increased spacing
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Increased spacing and eventual discontinuation of TNF blockers after 6 months
Trial: 18729243
Drug: Garcinia cambogia
RxNorm normalized name: Garcinia Cambogia Fruit
DrugBank: Garcinia gummi-gutta fruit (DB14365)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Garcinia cambogia (2.4 g) plus Amorphophallus konjac (1.5 g)
Trial: 17296074
Drug: Promotion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Promotion of one's coping resources therapy
Trial: 12806521
Drug: Triptans (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triptans (various formulations including oral tablets, orally disintegrating tablets, nasal sprays, subcutaneous injections, suppositories)
Trial: 4061004
Drug: Adrenaline 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adrenaline 0.5 mg i.v.
Trial: 22517217
Drug: Azelnidipine (AZ)
RxNorm normalized name: Azelnidipine
DrugBank: Azelnidipine (DB09230)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azelnidipine (AZ) 16 mg
Trial: 10966962
Drug: Buffered solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buffered solution (solution B) - 5 ml 2% lignocaine and 5 ml 0.5% bupivacaine with pH 7.44
Trial: 897632
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy with cyclophosphamide, methotrexate and fluorouracil (CMF)
Trial: 23756431
Drug: Anodal transcranial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anodal transcranial direct current stimulation (A-tDCS) for 10 minutes at 1 mA in the DLPFC, followed by rehabilitative cognitive training, daily for 15 days
Trial: 19386430
Drug: Tegafur-uracil (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tegafur-uracil (300 mg/m²/d) and leucovorin (75 mg/d) from Days 1 to 19 and from Days 29 to 47, carboplatin (70 mg/m² intravenously for 4 consecutive days), in three cycles every 21 days, with radiotherapy (70 Gy in 35 fractions)
Trial: 17332612
Drug: Paroxetine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine (20 mg/d)
Trial: 16690005
Drug: Venlafaxine (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venlafaxine (150 mg/d)
Trial: 14624187
Drug: Venlafaxine (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venlafaxine (300 mg/d)
Trial: 16690005
Drug: Desipramine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desipramine (100 mg/d)
Trial: 16690005
Drug: Nefazodone (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nefazodone (300 mg/d)